Skip to main content
Two gloved hands with tweezers holding the PBTE cell engager for use in a scientific experiment.Blog posts

Enhancing efficacy against clear cell renal cell carcinoma through format-tuning of bispecific T cell engagers

Key takeaways Researchers have examined how format-tuning bispecific T cell engagers (BTEs) boosts therapeutic efficacy against clear cell renal cell carcinoma (ccRCC). Using a novel persistent multivalent T cell engager (PMTE) to enhance cell avidity and tumor targeting, they tackle challenges like low plasma half-life, poor tumor retention, and antigen…
Andrea Candelli
29 January 2025
Press releases

Dutch Life Science Tools LUMICKS secures €20 million from European Investment Bank to accelerate drug discovery for cancer

Amsterdam-based LUMICKS signs €20 million venture debt with EIB to accelerate the development and launch of its new product, designed to advance immunotherapy development for cancer research.  LUMICKS’ next generation high-throughput cell avidity platform aims to transform the drug discovery process by replacing traditional screening methods, expediting development for life-saving…
Chenlu Yu
10 October 2024
Blog posts

Key mechanism in Fanconi Anemia pathway discovered with the C-Trap

Explore groundbreaking research on the FANCD2-I complex, central to the Fanconi anemia pathway, and its newly discovered mechanism in DNA repair and replication fork protection. This deep dive details the latest insights from recent studies, elucidating the complex's role in genomic stability and potential implications for cancer therapy.
Chenlu Yu
1 August 2024
Blog posts

Cell Avidity screening deployed by T cell pioneers to accelerate the identification of functional TCRs

The TCR field continues to rely on a protracted preclinical selection process, which utilizes conventional assays such as affinity and peptide titrations that correlate poorly with T-cell functionality. Optimal TCR selection necessitates thorough preclinical characterization, prompting Carr et al., to focus on comprehensive cell-cell binding assessment to enhance preclinical decision-making.
niels
25 June 2024
Close Menu

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us


Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:

 

Download our Cell Therapy (CAR-T, TCR, NK) applications deck